Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05374447 · ClinicalTrials.gov registry record · NA
Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy
A NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy, sponsored by George Washington University.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05374447: Recruiting NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy, sponsored by George Washington University.
NCT05374447 is a NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy that is actively recruiting participants, run by George Washington University. The registered enrollment target is 55 participants, below the 88-participant average among 3 other Sarcoidosis, Pulmonary trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05374447, a NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy, is actively recruiting participants, sponsored by George Washington University.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.
Primary Outcome
Diagnostic yield of EBUS-TBNA + EBUS-IFB compared to EBUS-TBNA alone
Conditions Studied
Interventions
- PROCEDURE Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy
Study Locations (1)
District of Columbia
- The George Washington University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What NCT05374447 shows while recruiting
NCT05374447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 88-participant average among 3 other Sarcoidosis, Pulmonary trials with a reported enrollment target (37% lower).
The record links to 3 conditions, with Sarcoidosis, Pulmonary appearing as the primary indexed condition, and to 1 intervention - of which Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy is the first listed.
NCT05374447 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05374447 about?
NCT05374447 is a clinical study titled "Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy". The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.
What is the current status of trial NCT05374447?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2022-06-10. Estimated completion is 2026-03-01.
What conditions does trial NCT05374447 study?
This clinical trial studies the following conditions: Sarcoidosis, Pulmonary, Mediastinal Lymphadenopathy, Mediastinal Diseases.
What interventions are being tested in trial NCT05374447?
The interventions under investigation include: Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05374447?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05374447 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis, Pulmonary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI